Data from first real-world study of how the Pfizer-BioNTech shot holds up against Omicron show big drop-off in effectiveness against infection
Covid-19 vaccine lowered the risk of hospital admission by 70% for patients infected with the highly mutated variant.
The study examined 211,610 positive Covid-19 test results in adults reported since the beginning of September. It used that data to compare vaccine effectiveness during September and October, when Delta was dominant, with the three-week period between Nov. 15 and Dec. 7, when Omicron took hold. Discovery Health insures around 3.7 million people in South Africa.
The findings build on earlier, laboratory-based research from various groups around the world examining how well the blood of vaccinated people neutralizes the Omicron variant.
Protection against severe disease appeared to decline with age, but the researchers cautioned that the data was uncertain and could be complicated by a larger waning effect in older groups, who would have received their shots earlier. The researchers also found that Omicron eroded the protective effect of prior infection.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
South Africa study shows two Pfizer shots may halt 70% of omicron hospitalizations: reportTwo shots of the COVID vaccine produced by Pfizer undefined and BioNTech undefined may offer 70% protection against hospitalizations due to the omicron...
Baca lebih lajut »
Pfizer jabs protect 70% against hospitalization from omicronA two-dose Pfizer/BioNTech vaccination provides just 33% protection against infection by the omicron variant of the coronavirus, but 70% protection against hospitalization, according to a large-scale analysis in South Africa.
Baca lebih lajut »
Pfizer vaccine protecting against hospitalisation during Omicron wave - studyTwo doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant.
Baca lebih lajut »
Pfizer says its COVID-19 treatment pill works against the Omicron variantThe company says the full results of its study of the pill confirm promising early findings of the drug's protection against hospitalization and death.
Baca lebih lajut »
Pfizer confirms COVID pill's results, potency versus omicronPfizer said Tuesday that its experimental COVID-19 pill appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed the pill's promising early results against the virus: The drug reduced combined hospitalizations and deaths by about 89% among high-risk adults when taken shortly after initial COVID-19 symptoms. Separate laboratory testing shows the drug retains its potency against the omicron variant, the company announced, as many experts had predicted. Pfizer tested the antiviral drug against a man-made version of a key protein that omicron uses to reproduce itself.
Baca lebih lajut »
Pfizer Says Its Covid-19 Pill Likely Works Against OmicronPfizer’s Covid-19 pill, which is up for FDA authorization, worked against Omicron in lab tests, the company said. A final analysis of a key study also confirmed the drug was 89% effective in high-risk adults.
Baca lebih lajut »